Belief BioMed Completed Dosing of the First Subject in the Registrational Gene Therapy Clinical Trial for Hemophilia B

/PRNewswire/ -- On December 30th, 2021, Belief BioMed Group (BBM) announced that it has successfully dosed the first subject in the registrational gene therapy...

Related Keywords

China ,Shanghai ,Xiao ,Belief Biomed Group ,Belief Biomed ,Chief Science Officer ,Investigator Initiated Trial ,Belief Biomed Inc ,